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Abstract Altered modulation of skeletal muscle voltage-gated 
sodium channels by myotonic dystrophy kinase (DMPK) has 
been proposed as a possible mechanism underlying myotonia in 
this disease. We examined the effect of a recombinant mouse 
DMPK on the functional properties of human skeletal muscle 
(hSkMl) and cardiac (hHl) voltage-gated sodium channels in 
the Xenopus oocyte expression system. Co-expression of DMPK 
with hSkMl in oocytes resulted in significantly lower peak 
sodium current amplitude as compared to cells expressing 
hSkMl alone in agreement with a previous report. By contrast, 
DMPK had no effect on the level of expressed sodium current in 
cells expressing hHl. Similarly, there were no measurable effects 
of the kinase on the kinetics or steady-state properties of 
activation or inactivation. Our findings support the previous 
observations made with rat muscle sodium channels and 
demonstrate that the effect of DMPK on sodium channels is 
isoform specific despite conservation of a putative phosphoryla-
tion site between the two isoforms. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Myotonic dystrophy is the most common form of muscular 
dystrophy affecting adults [1]. Although the syndrome is 
named for its muscular manifestations (myotonia, muscular 
wasting, and weakness), the disease involves many systems 
including skin, central nervous system, eye, and heart. Trans-
mission is autosomal dominant, and the genetic defect is a 
trinucleotide (CTG) repeat expansion within the 3'-untrans-
lated region of a putative protein kinase gene located on 
chromosome 19ql3.3 [2-A]. 
Although the genetic basis of the disease has been solved, 
less is known about the cellular defect responsible for the 
pleiotropic disease manifestations. Recently, Mounsey et al. 
reported an effect of the normal myotonic dystrophy gene 
product (DMPK) on a recombinant skeletal muscle voltage-
gated sodium channel [5]. In co-expression experiments per-
formed in Xenopus oocytes, DMPK caused a significant re-
duction in peak sodium channel current amplitude without 
affecting the time course of channel activation or inactivation. 
This effect was prevented by a site specific mutation of a 
conserved protein kinase C (PKC) phosphorylation site (ser-
ine 1321), located within the cytoplasmic linker region be-
tween repeat domains 3 and 4 (ID3^l). The investigators con-
cluded that altered levels of the kinase in muscle cells of 
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patients with myotonic dystrophy could cause altered sarco-
lemmal excitability and myotonia. More recently, DMPK has 
been shown capable of directly phosphorylating sodium chan-
nel pep tide sequences in vitro [6]. These observations all point 
to the potential modulation of voltage-gated sodium channels 
by DMPK as a potential explanation for certain manifesta-
tions of the muscular phenotype. 
Overt cardiac disease is unusual in myotonic dystrophy, but 
a majority of patients exhibit subclinical electrocardiographic 
or echocardiographic abnormalities, and are at increased risk 
for sudden cardiac death [7]. Myocardial cells express both 
DMPK, and a unique isoform of voltage-gated sodium chan-
nel a subunit, that is distinguished from brain and skeletal 
muscle channels by its lower sensitivity to the neurotoxin te-
trodotoxin. Molecular cloning of the human cardiac sodium 
channel [8] has revealed a significant amino acid sequence 
similarity with the skeletal muscle sodium channel including 
conservation of the protein kinase C phosphorylation site 
within the ID3^4 region that is the putative target of DMPK. 
In this report, we examined the effect of a recombinant 
mouse DMPK on functional expression of the human cardiac 
sodium channel a subunit expressed heterologously in Xeno-
pus oocytes. Our initial hypothesis was that, like skeletal 
muscle sodium channels, DMPK would modulate the func-
tional activity of the cardiac isoform and this might help ex-
plain the cardiac phenotype of myotonic dystrophy. However, 
as we report here, DMPK modulates skeletal muscle but not 
cardiac sodium channels expressed in Xenopus oocytes. There-
fore, DMPK modulation of sodium channels differs between 
muscle and heart isoforms and suggests that factors other 
than a conserved PKC phosphorylation site in the ID3^4 link-
er may be required for the effect observed in muscle sodium 
channels. 
2. Materials and methods 
2.1. Expression of mouse DMPK 
Full-length mouse DMPK cDNA [9] was subcloned into the oocyte 
expression vector pSP64T [10], and junctional regions were sequenced 
to verify correct assembly. The resulting plasmid, designated as 
pSP64T-DMK, was made linear by Xba\ digestion, and used for in 
vitro transcription using SP6 RNA polymerase in the presence of the 
methylated 5'-cap analog m7GpppG. Transcripts were checked for 
size, purity, and concentration on denaturing agarose/formaldehyde 
gels. 
2.2. Expression of sodium channels in Xenopus oocytes 
In vitro transcriptions of human skeletal muscle (hSkMl) and hu-
man cardiac (hHl) sodium channel a subunits, and the human so-
dium channel Pi subunit were performed as previously described [11]. 
Xenopus oocytes were procured, defolliculated, and microinjected as 
previously described [12]. In co-expression experiments, sodium chan-
nel a subunit cRNA or an equal part mixture of a and [Si subunit 
cRNAs was diluted with an equal volume of DMPK cRNA, or nu-
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clease free water. After injection, oocytes were incubated at 18°C in a 
dilute solution of Leibovitz's L-15 medium (Gibco, Grand Island, 
NY) enriched with 15 mM 4-(2-hydroxyethyl)-l-piperazine-methane-
sulfonic acid (HEPES, adjusted to pH 7.6 with NaOH), 1 mM gluta-
mine, and 50 ug/ml gentamycin. Oocytes were used for experiments 
2-3 days after injection. 
2.3. Electrophysiology 
Whole-cell currents were recorded in oocytes using two microelec-
trode voltage-clamp as previously described [12]. Electrodes were 
pulled from Prism glass capillaries (Dagan Corp., Minneapolis, 
MN) and filled with 3 M KC1. Electrode resistances were 1-3 M£2 
for voltage recording electrodes and 0.5-1.5 M£2 for current passing 
electrodes. Experiments were conducted on oocytes from at least two 
different frogs. Membrane potential was controlled by a Warner oo-
cyte clamp (Warner Instrument Corp., Hamden, CT). A ground metal 
shield was inserted between the two electrodes to minimize coupling 
and speed the clamp rise-time. Voltage commands were generated by 
computer using pCLAMP version 5.5 software (Axon Instruments). 
Currents were filtered at 2 kHz (—3 dB; 4 pole Bessel filter). 
The holding potential was set to —120 mV and Na+ currents were 
recorded during test potentials to —20 mV for hSkMl and —30 mV 
for hHl . Test voltages were chosen to be at a membrane potential at 
which most Na + channels will open if available, and are not on the 
negative limb of the current voltage relationship for either hSkMl or 
hHl. Analyses were restricted to cells in which the voltage control was 
adequate. To assess steady-state channel inactivation, two-pulse pro-
tocols were employed. Membrane potential was stepped to a voltage 
between —120 mV and —20 mV for 500 ms, and then peak Na+ 
current was measured during a test potential. The prepulse duration 
used in these experiments was chosen based upon preliminary experi-
ments demonstrating that 500 ms was sufficient to allow steady-state 
inactivation to occur in both Na+ channel isoforms prior to the test 
pulse. 
2.4. Data analysis 
All measurements were made with pCLAMP. The steady-state in-
activation data were fit with a Boltzmann function, 
///max = {l +exp[(F-F1/2)//c]}" 
to determine the membrane potential for half maximal inactivation 
(Vi/2) and the slope factor k. The time course of current decay during 
a voltage step was assessed by measuring the time to half decay (7i/2). 
Results were presented as mean ± standard error of the mean 
(mean±S.E.M.). 
3. Results 
Fig. 1 illustrates the effect of DMPK on hSkMl sodium 
channels expressed in oocytes. Representative current tracings 
obtained at various test potentials are shown for oocytes in-
jected with hSkMl alone (Fig. 1A), or in oocytes expressing 
both hSkMl and DMPK (Fig. IB). Currents recorded from 
both groups of oocytes exhibit similar activation and inacti-
vation characteristics, but differ greatly in their peak current 
amplitudes. Oocytes expressing hSkMl and DMPK exhibit 
approximately 50% lower peak current amplitudes measured 
at a test potential of —10 mV than the corresponding cells 
injected with hSkMl alone (hSkMl alone: 8.4±1.2 uA, 
«=16; hSkMl+DMPK: 3.2±0.6 uA, n= 17; p<0.001, Fig. 
1C). There was no detectable effect of the kinase on the 
time course of inactivation, or in the voltage dependence of 
steady-state inactivation (data not shown). Also, there was no 
difference in the extent of current reduction mediated by 
DMPK when hSkMl was co-expressed with the human Pi 
subunit (data not shown). Our findings are similar to those 
reported by Mounsey et al. [5], who examined the effect of a 
recombinant human DMPK on rat skeletal muscle sodium 
channels expressed in oocytes, suggesting that the mouse 
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Fig. 1. Effect of mouse DMPK on hSkMl expressed in oocytes. (A) 
Representative voltage-clamp recordings made from an oocyte ex-
pressing hSkMl alone. Current tracings obtained at various test po-
tentials from a holding potential of —120 mV are shown. (B) Repre-
sentative voltage-clamp recordings made from an oocyte expressing 
hSkMl+DMPK using the same pulse protocol as shown in A. (C) 
Bar graph comparing peak sodium current measured at a test volt-
age of —20 mV between oocytes expressing hSkMl alone or 
hSkMl+DMPK. 
DMPK plasmid used in our study encodes a functional pro-
tein. 
By contrast, with the hSkMl isoform, the human cardiac 
sodium channel, hHl , was not modulated by co-expressed 
DMPK. Fig. 2 shows representative current tracings obtained 
from oocytes expressing either hHl alone (Fig. 2A), or hHl 
and DMPK (Fig. 2B). As was observed for hSkMl, DMPK 
had no effect on the time course of either activation or inac-
tivation. Furthermore, DMPK had no effect on hHl peak 
current amplitude measured at any test voltage. Fig. 2C shows 
a comparison between peak current amplitudes measured at a 
test potential of —10 mV in oocytes expressing either hHl 
alone or the combination of hHl with DMPK. There was 
no statistical difference between current amplitudes in cells 
expression hHl alone, and cells expressing hHl with DMPK 
(hHl alone: 10.5±1 uA, « = 1 1 ; hHl+DMPK: 11.2+1 uA, 
n- 12; p = 0.6). We examined the time course of sodium cur-
rent inactivation in both hHl expressing oocytes and cells 
expressing hHl and DMPK. There was no difference between 
the time required for 50% inactivation at any test voltage (Fig. 
3A). In addition, there was no effect of the kinase on the 
voltage dependence of steady-state inactivation (Fig. 3B). 
Similar results were obtained from several different batches 
of oocytes from separate frogs. We performed additional co-
expression experiments in the presence of the human (3i sub-
unit, and similarly found no measurable difference in any 
functional parameter of hHl. These results, by contrast to 
the data with hSkMl, demonstrate the lack of effect of 
DMPK on the cardiac sodium channel isoform. 
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4. Discussion 
The molecular basis of myotonic dystrophy involves a tri-
nucleotide expansion within the 3' untranslated region of a 
putative protein kinase gene [2-4]. There is current contro-
versy regarding the effect of this genetic mutation on cellular 
levels of the protein [13]. Evidence has been presented that the 
product of the DMPK gene is either increased [14], or de-
creased [15]. The protein product of the DMPK gene appears 
to function in vitro as a serine/threonine protein kinase [16], 
although its natural substrates have not been well defined. 
Clearly, much more work is needed to define the cellular 
pathogenesis of this multi-system disease. 
In the past few years, evidence that mutations in ion chan-
nels, which disrupt their function, can result in abnormalities 
in muscle membrane excitability. This has been best studied in 
two distinct forms of congenital myotonia. In paramyotonia 
congenita and hyperkalemic periodic paralysis, mutations in 
the human skeletal muscle voltage-gated sodium channel a 
subunit gene (SCN4A, 17q), have been identified and shown 
to cause significant channel dysfunction [17]. Specifically, mu-
tations in either disorder can disrupt both fast and slow in-
activation, and have variable effects on the recovery from 
inactivation. In a clinically similar but genetically distinct dis-
order, myotonia congenita, mutations in a skeletal muscle 
chloride channel gene (CLCN1, 7q), have been linked to the 
pathogenesis of the syndrome [18,19]. It is tempting to spec-
ulate that myotonia, which can occur in a wide variety of 
inherited and acquired neuromuscular diseases, has a limited 
array of potential pathophysiologic mechanisms. In myotonic 
dystrophy, a previous hypothesis to explain myotonia, was 
that there is an indirect effect on sarcolemmal ion channels 
stemming from abnormalities in the lipid environment of the 
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Fig. 3. Effect of DMPK on hHl inactivation. (A) Voltage depend-
ence of inactivation half-time ( r ^ ) measured in oocytes expressing 
hHl alone (•), or hHl+DMPK ( r ) . (B) Voltage dependence of 
steady-state inactivation determined for hHl alone (•), or 
hHl+DMPK (T). 
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Fig. 2. Effect of mouse DMPK on hHl expressed in oocytes. (A) 
Representative voltage-clamp recordings made from an oocyte ex-
pressing hHl alone. Current tracings obtained at various test poten-
tials from a holding potential of —120 mV are shown. (B) Repre-
sentative voltage-clamp recordings made from an oocyte expressing 
hHl+DMPK using the same pulse protocol as shown in A. (C) Bar 
graph comparing peak sodium current measured at a test voltage of 
—30 mV between oocytes expressing hHl alone or hHl+DMPK. 
muscle cell membrane [20]. One study, attempting to find 
evidence in support of channel dysfunction, identified abnor-
malities in the time constants of sodium channel activation 
and inactivation in myoballs cultured from myotonic dystro-
phy muscle [21]. Therefore, there are some inconsistencies 
between this previous study using human muscle tissue, and 
the effect of DMPK on recombinant sodium channels. In our 
study, we examined the effect of the wild-type gene product 
and, therefore we have not excluded the possibility that alter-
ations of sodium channel function, as described by Riidel et 
al. [21], occur in the presence of the mutant DMPK transcript. 
It is possible that in the absence of normal DMPK levels, 
alterations in muscle sodium channel function result in altered 
sarcolemmal excitability. 
Cardiac involvement in myotonic dystrophy is common but 
often not clinically apparent [7]. Abnormalities of the electro-
cardiogram can be found in a majority of patients, and in-
clude first degree AV block, intraventricular conduction de-
fects, and a variety of atrial and ventricular arrhythmias. The 
occurrence of ventricular arrhythmias may help explain an 
observed increased incidence of sudden death in myotonic 
dystrophy patients. Furthermore, an altered interaction be-
tween DMPK and cardiac ion channels could conceivably 
be responsible for some of these electrocardiographic abnor-
malities. It is known that in the congenital long QT syndrome, 
genetic mutations inducing specific dysfunction of cardiac so-
dium and potassium channels result in characteristic ventric-
ular arrhythmias and an increased propensity for sudden 
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death [22]. In contrast, primary myocardial involvement is 
rare in myotonic dystrophy. Histological evaluation has re-
vealed significant fibrosis, fatty infiltration, and atrophy of 
the cardiac conduction tissue [23,24] supporting the view 
that selective involvement of the conduction tissue, rather 
than a generalized cardiomyopathy, accounts for most of 
the clinical cardiac problems seen in this disease. 
We sought to examine the effect of the wild-type DMPK 
gene product on the functional characteristics of two recombi-
nant human voltage-gated sodium channels, hSkMl and hHl. 
As reported previously by Mounsey et a l , DMPK has a pro-
found effect on the level of expressed current in oocytes ex-
pressing the muscle sodium channel isoform [5]. This effect is 
not accompanied by detectable changes in the kinetic proper-
ties of the channel, or in the voltage dependence of steady-
state inactivation. We obtained similar results whether oocytes 
expressed the a subunit alone, or in combination with a re-
combinant human pi subunit. These observations provide evi-
dence that the full-length mouse DMPK used in our study 
encodes a functional protein. By contrast, DMPK had no 
discernible functional effect on the recombinant human car-
diac sodium channel, hHl . This was a surprising result con-
sidering that the phosphorylation site considered to be a po-
tential target for DMPK, is conserved in both hSkMl and 
hHl. It is conceivable that despite preservation of this site, 
phosphorylation may exert distinct functional effects on the 
two different sodium channel isoforms possibly because the 
effect of the kinase depends upon concomitant phosphoryla-
tion of other sites. Alternatively, the amino acid sequence 
requirements for DMPK phosphorylation may not strictly 
match that of PKC, and differences between hSkMl and 
hHl within the ID3-4 region or elsewhere may determine 
the substrate specificity of the kinase. In view of the distinct 
functional effects exerted by DMPK on hSkMl and hHl, an 
experimental approach utilizing chimeras between the two so-
dium channel isoforms might provide information regarding 
these substrate determinants. 
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